Mostrar el registro sencillo del ítem

dc.contributor.authorSalazar-Mendiguchía, Joel
dc.contributor.authorPablo Ochoa, Juan
dc.contributor.authorPalomino-Doza, Julián
dc.contributor.authorDomínguez, Fernando
dc.contributor.authorDíez-­López, Carles
dc.contributor.authorAkhtar, Mohammed
dc.contributor.authorRamiro-­León, Soraya
dc.contributor.authorClemente, María M.
dc.contributor.authorPérez-­Cejas, Antonia
dc.contributor.authorRobledo, María
dc.contributor.authorGómez-Díaz, Iria
dc.contributor.authorPeña-Peña, María Luisa
dc.contributor.authorPeña-Peña, María Luisa
dc.contributor.authorCliment, Vicente
dc.contributor.authorSalmerón-Martínez, Francisco
dc.contributor.authorHernández, Celestino
dc.contributor.authorGarcía-­Granja, Pablo E.
dc.contributor.authorMogollón, M. Victoria
dc.contributor.authorCárdenas-­Reyes, Ivonne
dc.contributor.authorCicerchia, Marcos
dc.contributor.authorGarcía-­Giustiniani, Diego
dc.contributor.authorLamounier, Arsonval Jr.
dc.contributor.authorGil-Fournier, Belén
dc.contributor.authorDíaz-Flores, Felícitas
dc.contributor.authorSalguero, Rafael
dc.contributor.authorSantomé, Luis
dc.contributor.authorSyrris, Petros
dc.contributor.authorOlivé, Montse
dc.contributor.authorGarcía Pavía, Pablo 
dc.contributor.authorOrtiz-­Genga, Martín
dc.contributor.authorElliott, Perry M.
dc.contributor.authorMonserrat, Lorenzo
dc.date.accessioned2021-10-20T14:31:51Z
dc.date.available2021-10-20T14:31:51Z
dc.date.issued2020
dc.identifier.issn1355-6037spa
dc.identifier.urihttp://hdl.handle.net/10641/2507
dc.description.abstractObjective Up to 50% of patients with hypertrophic cardiomyopathy (HCM) show no disease-causing variants in genetic studies. TRIM63 has been suggested as a candidate gene for the development of cardiomyopathies, although evidence for a causative role in HCM is limited. We sought to investigate the relationship between rare variants in TRIM63 and the development of HCM. Methods TRIM63 was sequenced by next generation sequencing in 4867 index cases with a clinical diagnosis of HCM and in 3628 probands with other cardiomyopathies. Additionally, 3136 index cases with familial cardiovascular diseases other than cardiomyopathy (mainly channelopathies and aortic diseases) were used as controls. Results Sixteen index cases with rare homozygous or compound heterozygous variants in TRIM63 (15 HCM and one restrictive cardiomyopathy) were included. No homozygous or compound heterozygous were identified in the control population. Familial evaluation showed that only homozygous and compound heterozygous had signs of disease, whereas all heterozygous family members were healthy. The mean age at diagnosis was 35 years (range 15–69). Fifty per cent of patients had concentric left ventricular hypertrophy (LVH) and 45% were asymptomatic at the moment of the first examination. Significant degrees of late gadolinium enhancement were detected in 80% of affected individuals, and 20% of patients had left ventricular (LV) systolic dysfunction. Fifty per cent had non-sustained ventricular tachycardia. Twenty per cent of patients suffered an adverse cerebrovascular event (20%). Conclusion TRIM63 appears to be an uncommon cause of HCM inherited in an autosomal-recessive manner and associated with concentric LVH and a high rate of LV dysfunction.spa
dc.language.isoengspa
dc.publisherHeartspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.titleMutations in TRIM63 cause an autosomal-recessive form of hypertrophic cardiomyopathy.spa
dc.typejournal articlespa
dc.type.hasVersionAMspa
dc.rights.accessRightsopen accessspa
dc.description.extent570 KBspa
dc.identifier.doi10.1136/heartjnl-2020-316913spa
dc.relation.publisherversionhttps://heart.bmj.com/content/106/17/1342spa


Ficheros en el ítem

FicherosTamañoFormatoVer
1342.full.pdf570.6KbPDFVer/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España